| 摘要 |
The present invention relates to a human anti-epidermal growth factor receptor Fab antibody. In the present invention, a high-affinity anti-EGFR human Fab antibody selected by means of the DVS-II method comprises a heavy-chain variable region and a light-chain variable region selected by means of screening, thereby making it possible to provide a pharmaceutical composition for treating tumours and a pharmaceutical composition for treating rectal cancer having high specificity for epidermal growth factor receptors. |
